Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
South Korea flag South Korea · Delayed Price · Currency is KRW
8,070.00
-200.00 (-2.42%)
Sep 11, 2026, 3:30 PM KST

KRX:007570 Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
277,956272,422268,678266,669247,773242,511
Other Revenue
----0-0-0
277,956272,422268,678266,669247,773242,511
Revenue Growth
0.65%1.39%0.75%7.63%2.17%-29.37%
Cost of Revenue
168,111156,142157,461150,265139,579137,865
Gross Profit
109,845116,280111,217116,404108,194104,646
Selling, General & Admin
89,30482,08873,90773,60569,59169,145
Research & Development
28,82026,09924,74023,74822,39516,829
Other Operating Expenses
2,1002,0241,9671,9541,8321,764
Operating Expenses
123,573111,318101,595100,02493,94589,458
Operating Income
-13,7274,9639,62216,37914,24915,188
Interest Expense
-2,897-3,031-2,932-3,225-2,132-1,894
Interest & Investment Income
555.4502.77619.4361.43279.06348.43
Earnings From Equity Investments
-1,593-843.992,083-13,42510,7549,236
Currency Exchange Gain (Loss)
1,390-188.291,222-1,011-551.531,265
Other Non Operating Income (Expenses)
38,46111,730263.21-928.61,288-2,347
EBT Excluding Unusual Items
22,18913,13210,878-1,84923,88721,797
Gain (Loss) on Sale of Investments
284.06-27.788.92-24.78-
Gain (Loss) on Sale of Assets
39.8490.04-8.960.5321.222.86
Asset Writedown
44.04372.1540.51-36.82263.19
Pretax Income
22,55713,26010,899-1,79923,84622,063
Income Tax Expense
5,1966,1271,617230.974,0407,311
Earnings From Continuing Operations
17,3607,1339,282-2,03019,80614,752
Minority Interest in Earnings
-67.86-227.99-250.39-378.26-420.96-719.83
Net Income
17,2936,9059,032-2,40919,38514,032
Preferred Dividends & Other Adjustments
451.64177.95--88.03452.64-
Net Income to Common
16,8416,7279,032-2,32118,93314,032
Net Income Growth
66.40%-25.52%--34.92%28.98%
Shares Outstanding (Basic)
171818181818
Shares Outstanding (Diluted)
171818181818
Shares Change
-4.40%-2.63%2.29%-0.59%-0.44%-
EPS (Basic)
968.50374.81490.00-128.791044.53770.78
EPS (Diluted)
968.50374.81490.00-131.001044.53770.78
EPS Growth
74.06%-23.51%--35.52%29.11%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
28,3266,323-32,5858,7361,93839,057
Free Cash Flow Per Share
1629.00352.33-1767.81484.85106.902145.40
Dividend Per Share
---150.000--
Dividend Growth
------
Gross Margin
39.52%42.68%41.39%43.65%43.67%43.15%
Operating Margin
-4.94%1.82%3.58%6.14%5.75%6.26%
Profit Margin
6.06%2.47%3.36%-0.87%7.64%5.79%
Free Cash Flow Margin
10.19%2.32%-12.13%3.28%0.78%16.11%
EBITDA
-5,26113,30719,44628,35026,01626,415
EBITDA Margin
-1.89%4.88%7.24%10.63%10.50%10.89%
D&A For EBITDA
8,4678,3449,82411,97111,76711,227
EBIT
-13,7274,9639,62216,37914,24915,188
EBIT Margin
-4.94%1.82%3.58%6.14%5.75%6.26%
Effective Tax Rate
23.04%46.21%14.84%-16.94%33.14%
Advertising Expenses
-6,7156,4096,2646,3127,205